Latest News

STAT Plus: Something Ventured: Casma Therapeutics and four other startups got venture funding a year ago. Did it help them do what they said it would?

Early-stage biotech companies can make some big promises to their investors — lofty claims that they’re creating the first drug to treat a disease or first to use a new kind of biology or chemistry. And in return for those promises, investors hand over millions of dollars.

But early-stage companies are private. For outsiders, sporadic press releases contain clues about where a company’s headed — but asking the company’s leadership and staff is the only real way to find out exactly what’s going on.

Continue to STAT Plus to read the full story…

Source link

Related posts

Research uncovers new evidence of the link between air pollution and cancer


Cells in humans are affected by thirdhand smoke, study shows


Disneyland Visitors May Have Been Exposed to Measles


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy